Dude I love your optimism. Still the company needs about 12M a year to run. The cap now is not that much higher circa 17M. See the issue? They just can't sell enough shares to fund the thing and new money will be near impossible to come by as fundies will be out and Hishenk will only go so far.
They need to get the SP up a lot or cut costs alot. Ther is no talk of this.
I think they started to believe thier own press as they say and didn't plan for the more likely scenario that the drug may need more time or even fail. This is a mistake that Hopper or Kelly would not make. They are clueless to investors. Look at the options reversal. They just don't get it.
The only thing to consider there is do you take the tax loss now or maybe they liquidators sell the drug for more and return a dividend that way. The lights are still on for now but nobody is home.
KZA Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held
